Melioidosis: Epidemiology, Pathophysiology, and Management
Top Cited Papers
- 1 April 2005
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 18 (2) , 383-416
- https://doi.org/10.1128/cmr.18.2.383-416.2005
Abstract
SUMMARY: Melioidosis, caused by the gram-negative saprophyteBurkholderia pseudomallei, is a disease of public health importance in southeast Asia and northern Australia that is associated with high case-fatality rates in animals and humans. It has the potential for epidemic spread to areas where it is not endemic, and sporadic case reports elsewhere in the world suggest that as-yet-unrecognized foci of infection may exist. Environmental determinants of this infection, apart from a close association with rainfall, are yet to be elucidated. The sequencing of the genome of a strain ofB. pseudomalleihas recently been completed and will help in the further identification of virulence factors. The presence of specific risk factors for infection, such as diabetes, suggests that functional neutrophil defects are important in the pathogenesis of melioidosis; other studies have defined virulence factors (including a type III secretion system) that allow evasion of killing mechanisms by phagocytes. There is a possible role for cell-mediated immunity, but repeated environmental exposure does not elicit protective humoral or cellular immunity. A vaccine is under development, but economic constraints may make vaccination an unrealistic option for many regions of endemicity. Disease manifestations are protean, and no inexpensive, practical, and accurate rapid diagnostic tests are commercially available; diagnosis relies on culture of the organism. Despite the introduction of ceftazidime- and carbapenem-based intravenous treatments, melioidosis is still associated with a significant mortality attributable to severe sepsis and its complications. A long course of oral eradication therapy is required to prevent relapse. Studies exploring the role of preventative measures, earlier clinical identification, and better management of severe sepsis are required to reduce the burden of this disease.Keywords
This publication has 431 references indexed in Scilit:
- Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shockIntensive Care Medicine, 2004
- A Mutant ofBurkholderia pseudomallei, Auxotrophic in the Branched Chain Amino Acid Biosynthetic Pathway, Is Attenuated and Protective in a Murine Model of MelioidosisInfection and Immunity, 2002
- Melioidosis: An Emerging Infection in Taiwan?Emerging Infectious Diseases, 2001
- Cytokine Gene Expression in Innately Susceptible BALB/c Mice and Relatively Resistant C57BL/6 Mice during Infection with VirulentBurkholderia pseudomalleiInfection and Immunity, 2000
- Polymorphism in the promoter region of tumor necrosis factor-alpha gene is associated with severe melioidosisHuman Immunology, 1999
- The many facets of melioidosisTrends in Microbiology, 1999
- Experimental Melioidosis in Inbred Mouse StrainsZentralblatt für Bakteriologie, 1996
- RAPD analysis of isolates ofBurkholderia pseudomalleifrom patients with recurrent melioidosisEpidemiology and Infection, 1995
- Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptideBiochemical and Biophysical Research Communications, 1987
- Laboratory-Acquired Infection withPseudomonas pseudomallei(Melioidosis)New England Journal of Medicine, 1981